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ABSTRACT
Programmed cell death 4 (PDCD4) is a RNA-binding
protein that acts as a tumor suppressor in many cancer
types, including colorectal cancer (CRC). During CRC
carcinogenesis, PDCD4 protein levels remarkably
decrease, but the underlying molecular mechanism for
decreased PDCD4 expression is not fully understood. In
this study, we performed bioinformatics analysis to
identify miRNAs that potentially target PDCD4. We
demonstrated miR-181b as a direct regulator of PDCD4.
We further showed that activation of IL6/STAT3 signaling
pathway increased miR-181b expression and conse-
quently resulted in downregulation of PDCD4 in CRC
cells. In addition, we investigated the biological effects
of PDCD4 inhibition by miR-181b both in vitro and
in vivo and found that miR-181b could promote cell
proliferation and migration and suppress apoptosis in
CRC cells and accelerate tumor growth in xenograft
mice, potentially through targeting PDCD4. Taken toge-
ther, this study highlights an oncomiR role for miR-181b
in regulating PDCD4 in CRC and suggests that miR-181b
may be a novel molecular therapeutic target for CRC.
KEYWORDS microRNA, colorectal cancer, miR-181b,
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INTRODUCTION
Colorectal cancer (CRC) is a major worldwide health prob-
lem due to its high prevalence and mortality rate. In the USA,
CRC is currently the third most common cancer type and the
third leading cause of cancer-related death (Siegel et al.,
2015). Although there has been a recent increase in the
understanding, diagnosis and treatment of CRC, the exact
mechanisms contributing to the origin and development of
CRC remain complex and unclear.
In general, CRC results from an accumulation of genetic
and epigenetic changes in colon epithelial cells. Among the
myriad causes of CRC, oncogene activation (e.g., KRAS
and IGF1R) and tumor suppressor gene silencing (e.g., APC
and RET) play vital roles during tumorigenesis (Downward,
2003; Luo et al., 2013; Su et al., 2014; Dow et al., 2015). In
recent years, programmed cell death 4 (PDCD4) has
received considerable attention as a tumor suppressor pro-
tein (Biyanee et al., 2015). PDCD4 is a nuclear-cytoplasmic
shuttling and RNA-binding protein involved in controlling the
translation of speciﬁc mRNAs. Recent ﬁndings indicate that
PDCD4 can function as a protein translation suppressor
though both eIF4A-dependent or -independent pathways
(Yang et al., 2003; Yang et al., 2004; Singh et al., 2011;
Wedeken et al., 2011). PDCD4 is widely recognized as an
important tumor suppressor, as its expression is dramatically
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downregulated in many cancer types, including CRC (Yang
et al., 2006), lung cancer (Chen et al., 2003), breast cancer
(Gonzalez-Villasana et al., 2012) and gastric cancer (Guo
et al., 2013). Several studies have validated that loss of
PDCD4 during tumorigenesis promotes cancer cell prolifer-
ation (Li et al., 2014), metastasis (Yang et al., 2006) and
inhibits apoptosis (Wang et al., 2010b). Although our
knowledge about PDCD4 has quickly increased in recent
years, there is still much work to be done to elucidate how
PDCD4 expression is regulated during carcinogenesis.
MicroRNAs (miRNAs) are small (19–23 nucleotides) non-
coding RNA molecules (He and Hannon, 2004). In general,
miRNAs act as endogenous suppressors of gene expression
by binding to the 3′-untranslated region (3′-UTR) of target
mRNAs to induce translational repression or mRNA cleav-
age (Bushati and Cohen, 2007). Since their discovery,
miRNAs have gained attention as post-transcriptional regu-
lators in many biological processes, including cancer
(Esquela-Kerscher and Slack, 2006). Years of continued
research on miRNAs have revealed that many miRNAs
directly correlate with human cancers and that these miR-
NAs can function as tumor suppressor miRNAs or oncomiRs
(Esquela-Kerscher and Slack, 2006). Abnormal miRNA
expression also plays a pivotal role during CRC initiation,
and some miRNAs directly regulate CRC cell proliferation,
invasion and apoptosis. Among the miRNAs correlated with
tumorigenesis, miR-181b is one of the most important. miR-
181b was reported to be signiﬁcantly overexpressed in CRC
(Nakajima et al., 2006; Xi et al., 2006; Schetter et al., 2008;
Degagne et al., 2014; Liu et al., 2014) and is associated with
the poor prognosis of CRC patients (Schetter et al., 2008),
indicating that miR-181b may be involved in the pathogen-
esis of CRC as an oncogene. Conversely, miR-181b has
been found to be frequently downregulated in CRC samples
due to higher hypermethylation and exert tumor-suppressive
effects (Zhao et al., 2016). Thus, whether miR-181b func-
tions as an oncogene or a tumor suppressor is dependent on
the cell and tumor types, and miR-181b may exert different
functions under different circumstances. Overall the ﬁndings
of ours and others highlight distinguishing characteristics of
miR-181b in both promoting and suppressing colorectal
tumorigenesis. Thus, the molecular mechanism underlying
the contribution of miR-181b to CRC development and pro-
gression needs to be fully elucidated.
STAT3, a transcription factor activated by IL-6, is closely
associated with CRC (Morikawa et al., 2011; Pradhan et al.,
2012; Waldner et al., 2012). Increased IL-6 expression has
been correlated with advanced disease stage and
decreased survival of CRC patients, and several therapeu-
tics targeting the IL6/STAT3 signaling pathway have been
developed as a promising strategy for treatment of CRC
(Waldner et al., 2012). It is important to note that a large part
of the functions of IL-6/STAT3 pathway resulted from their
abilities to regulate downstream miRNAs (Iliopoulos et al.,
2010; Degagne et al., 2014). One interesting example is that
STAT3 directly activates transcription of miR-21 and miR-
181b during the transformation process (Iliopoulos et al.,
2010). Thus, investigating the functions of the downstream
miRNAs of the IL6/STAT3 signaling pathway may contribute
to our understanding of the molecular mechanisms under-
lying CRC development.
Although PDCD4, miR-181b and IL6/STAT3 signaling
pathway are tightly associated with CRC carcinogenesis, it is
necessary to explore their relationship and uncover the
regulatory network constituted by them. In this study, we
found that miR-181b, as an IL-6/STAT3-activated miRNA,
directly targets PDCD4 to promote CRC cell proliferation and
migration and to inhibit apoptosis in vitro and accelerate
tumor growth in vivo.
RESULTS
CRC tissues exhibit downregulation of PDCD4 protein
but not mRNA
We ﬁrst examined PDCD4 expression patterns in human
CRC tissues. After measuring PDCD4 protein levels in 14
pairs of CRC tissues and normal adjacent tissues, we found
that PDCD4 protein levels were dramatically decreased in
CRC tissues compared to normal adjacent tissues (Fig. 1A
and 1B). We then measured PDCD4 mRNA levels in the
same CRC tissue pairs and detected irregular alterations in
PDCD4 mRNA levels between the tumor and paired non-
tumor tissues (Fig. 1C). The inconsistency between PDCD4
protein and mRNA expression in CRC tissues suggests that
PDCD4 expression is regulated through a post-transcrip-
tional mechanism.
Identiﬁcation of PDCD4 as a miR-181b target
Because miRNA is an important and widely existing way to
post-transcriptionally regulate gene expression, we hypoth-
esized that some miRNAs regulated PDCD4 protein level in
CRC. We used a bioinformatics software Targetscan to
predict potential miRNAs that target PDCD4. We identiﬁed
miRNAs in the miR-181 family as the top candidates. There
are four miR-181 family members (miR-181a/b/c/d) encoded
by three independent transcripts on three separate chro-
mosomes. Among them, human miR-181a/b have more
gene copies (Ji et al., 2009) and higher expression levels
(Landgraf et al., 2007) than miR-181c/d. In addition, miR-
181a/b have been more closely implicated in cancer than
miR-181c/d, and have thus received more attention in the
miRNA ﬁeld (Mansueto et al., 2010; Wang et al., 2010a; Liu
et al., 2014; Parikh et al., 2014). For miR-181a/b, the mini-
mum free energy value of the hybrid between miR-181b and
the conserved binding site on the PDCD4 3′-UTR is -17.4
kcal/mol and is lower than that of miR-181a (−16.2 kcal/mol),
suggesting that miR-181b may bind more tightly to PDCD4
3′-UTR than miR-181a. Thus, we used miR-181b for further
experimentation. The predicted interaction between miR-
181b and PDCD4 3′-UTR is illustrated in Fig. 2A. There was
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perfect base-pairing between the seed region (the core
sequence that encompasses the ﬁrst 2–8 bases of the
mature miRNA) and the cognate target, and the miR-181b
binding sequence in the PDCD4 3′-UTR was highly con-
served across species (Fig. 2A).
We next examined whether miR-181b expression levels
inversely correlated with PDCD4 expression in CRC tissues.
We measured miR-181b levels in the same 14 pairs of CRC
tissues and corresponding normal tissues and found that the
miR-181b levels were consistently higher in CRC tissues
(Fig. 2B), which was consistent with the idea that miRNA
levels are inversely correlated to the levels of their targets.
We further illustrated the inverse correlation between miR-
181b and PDCD4 protein levels (Fig. 2C) and the disparity
between the miR-181b and PDCD4 mRNA levels (Fig. 2D)
using Pearson’s correlation scatter plots. Therefore, we
considered PDCD4 to be a miR-181b target based on
computational prediction and the inverse correlation
between miR-181b and PDCD4 protein levels in human
CRC tissues.
miR-181b directly regulates PDCD4 expression
at the post-transcriptional level
We further examined the inverse correlation between miR-
181b and PDCD4 by evaluating PDCD4 expression levels in
human CRC cells after miR-181b overexpression or knock-
down. Fig. 3A demonstrates efﬁcient miR-181b overex-
pression or knockdown in SW480 cells. As anticipated,
PDCD4 protein expression signiﬁcantly decreased upon
miR-181b overexpression, whereas treatment with the miR-
181b inhibitor increased PDCD4 protein levels in SW480
cells (Fig. 3B and 3C). We also examined PDCD4 mRNA
expression after transfection. miR-181b overexpression or
knockdown only slightly affected PDCD4 mRNA levels
(Fig. 3D). To demonstrate the robustness of the test, we
repeated the above experiments in two other CRC cell lines
(Caco2 and HT29) and observed consistent results (Fig. 3A–
D).
To determine whether miR-181b suppresses PDCD4
expression through direct interaction with the binding site in
the PDCD4 3′-UTR, we fused the PDCD4 3′-UTR sequence
containing the presumed miR-181b binding site into the
downstream region of the ﬁreﬂy luciferase gene in a reporter
plasmid. We transfected the resulting plasmid into SW480
cells along with the miR-181b mimic, miR-181b inhibitor or
scrambled negative control RNAs. As expected, miR-181b
overexpression resulted in an approximately 70% reduction
in luciferase reporter activity compared to cells transfected
with control mimic, whereas miR-181b inhibition resulted in a
30% increase in reporter activity compared to cells trans-
fected with the control inhibitor (Fig. 3E). We next con-
structed a mutant plasmid by introducing point mutations into
the miR-181b binding site in the PDCD4 3′-UTR to eliminate
miR-181b binding ability. The mutated luciferase reporter
was not affected by miR-181b overexpression or knockdown
(Fig. 3E). These results suggest that the binding site strongly
contributes to the miRNA-mRNA interaction.
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Figure 1. Downregulation of PDCD4 protein but not mRNA in CRC tissues. (A and B) Western blot analysis of PDCD4 protein
levels in 14 paired CRC (T) and normal adjacent tissue (N) samples. A: representative images; B: quantitative analysis.
(C) Quantitative RT-PCR analysis of PDCD4 mRNA levels in 14 paired CRC and normal adjacent tissue samples. *P < 0.05; **P <
0.01; ***P < 0.001.
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It has been previously reported that the CRC-related
transcription factor STAT3 (Morikawa et al., 2011; Pradhan
et al., 2012) can activate miR-181b (Iliopoulos et al., 2010;
Degagne et al., 2014). If PDCD4 is truly a miR-181b target,
the alteration of STAT3 levels would simultaneously affect
PDCD4 expression through miR-181b. To conﬁrm this
hypothesis, we used a STAT3 siRNA and a STAT3-speciﬁc
inhibitor Stattic (Schust et al., 2006) to suppress STAT3
expression and activity, respectively, and used IL-6 to acti-
vate STAT3 activity (Iliopoulos et al., 2010). As anticipated,
STAT3 siRNA and Stattic reduced miR-181b expression in
CRC cells, while IL-6 treatment increased miR-181b
expression (Fig. 3F). As a result, PDCD4 protein expression
exhibited an inverse alteration to STAT3 (Fig. 3G and 3H).
We also excluded the possibility that STAT3 is a direct reg-
ulator of PDCD4 by measuring the mRNA level of PDCD4
after the manipulation of the level or activity of STAT3.
PDCD4 mRNA levels were not affected by STAT3 siRNA,
Stattic (Schust et al., 2006) and IL-6 treatment (Fig. 3I),
suggesting that STAT3 might not directly inhibit PDCD4
expression at the transcriptional level.
miR-181b promotes CRC cell proliferation
and migration and suppresses apoptosis by targeting
PDCD4
We hypothesized that miR-181b promotes the CRC onco-
genic process by inhibiting PDCD4 expression. Thus, we
investigated the effects of miR-181b-driven PDCD4 repres-
sion on CRC cell proliferation, migration and apoptosis. We
ﬁrst performed CCK-8 and transwell assays to analyze the
effect of miR-181b on CRC cell proliferation and migration.
SW480 cells transfected with miR-181b mimic exhibited
increased proliferation and migration; in contrast, miR-181b
inhibition had the opposite effect on cell proliferation and
migration (Fig. 4A, 4C and 4D). We also investigated the
effects of miR-181b on apoptosis by ﬂow cytometric analy-
sis. The percentage of apoptotic cells was signiﬁcantly lower
A
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Tissue sample pairs
Fold change of PDCD4 protein level Fold change of PDCD4 mRNA level
R = - =R6087.0 -0.1523
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Figure 2. Identiﬁcation of PDCD4 as a miR-181b target. (A) Schematic description of the hypothetical duplex formed by the
interaction between the binding site in the PDCD4 3′-UTR (top) and miR-181b (bottom). The miR-181b seed region and the seed
sequence of its binding site in the PDCD4 3′-UTR are indicated in red. All nucleotides of the seed sequence of the binding site are
conserved in several species, including human, mouse and rat. The predicted free energy value of the hybrid is indicated.
(B) Quantitative RT-PCR analysis of miR-181b expression levels in the same 14 pairs of CRC and normal samples. (C) Pearson’s
correlation scatter plot of the fold change of miR-181b and PDCD4 protein in human CRC tissue pairs. (D) Pearson’s correlation
scatter plot of the fold change of miR-181b and PDCD4 mRNA in human CRC tissue pairs. *P < 0.05; **P < 0.01; ***P < 0.001.
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in SW480 cells transfected with miR-181b mimic and higher
in cells transfected with miR-181b inhibitor compared to
control cells (Fig. 4F and 4G).
However, it should be noted that transient transfection of
miRNA mimics typically gives rise to supraphysiological
miRNA levels in cells when the miRNA level is assessed by
qRT-PCR (Thomson et al., 2013). The supraphysiological
levels of transfected miRNA do not represent the functional
levels, because the majority of transfected miRNA is not
accessible for loading into Argonaute as functionally active
miRNAs, but is actually in non-functional locations such as in






























































































































































































































































































































































































Figure 3. miR-181b directly regulates PDCD4 expression at the post-transcriptional level. (A) Quantitative RT-PCR analysis of
miR-181b levels in SW480, Caco2 and HT-29 cells transfected with control mimic, miR-181b mimic, control inhibitor or miR-181b
inhibitor. (B and C) Western blot analysis of PDCD4 protein levels in SW480, Caco2 and HT-29 cells transfected with control mimic,
miR-181b mimic, control inhibitor or miR-181b inhibitor. B: representative images; C: quantitative analysis. (D) Quantitative RT-PCR
analysis of PDCD4 mRNA levels in SW480, Caco2 and HT-29 cells transfected with control mimic, miR-181b mimic, control inhibitor
or miR-181b inhibitor. (E) Direct binding of miR-181b to the PDCD4 3′-UTR. Fireﬂy luciferase reporters containing the wild-type (WT)
or mutant (MUT) form of human PDCD4 3′-UTR were cotransfected into SW480 cells along with control mimic, miR-181b mimic,
control inhibitor or miR-181b inhibitor. At 24 h post-transfection, the cells were assayed using a luciferase assay kit. Fireﬂy luciferase
values were normalized to β-galactosidase activity and plotted as relative luciferase activity. For comparison, the luciferase activity in
the control cells was set as 1. (F) Quantitative RT-PCR analysis of miR-181b levels in SW480 cells treated with control siRNA, STAT3
siRNA, DMSO, Stattic or IL-6. (G and H) Western blot analysis of PDCD4 protein levels in SW480 cells treated with control siRNA,
STAT3 siRNA, DMSO, Stattic or IL-6. G: representative images; H: quantitative analysis. (I) Quantitative RT-PCR analysis of PDCD4
mRNA levels in SW480 cells treated with control siRNA, STAT3 siRNA, DMSO, Stattic or IL-6. *P < 0.05; **P < 0.01; ***P < 0.001.
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Figure 4. Effects of miR-181b and PDCD4 on CRC cell proliferation, migration and apoptosis. (A) Cell proliferation assays were
performed 12, 24, 36, 48, 60 and 72 h after the transfection with equal dose of control mimic, miR-181b mimic, control inhibitor or miR-181b
inhibitor. (B) Cell proliferation assays were performed 12, 24, 36 and 48, 60 and 72 h after transfection with equal dose of the control mimic plus
control plasmid, miR-181b mimic plus control plasmid, control mimic plus PDCD4 overexpression plasmid, or miR-181b mimic plus PDCD4
overexpressionplasmid. (C–E)TranswellanalysisofSW480cells thatwere transfectedwithequaldoseofcontrolmimic,miR-181bmimic,control
inhibitorormiR-181b inhibitor (upperpanel),orwithequaldoseofcontrolmimicpluscontrolplasmid,miR-181bmimicpluscontrolplasmid,control
mimicplusPDCD4overexpressionplasmid, ormiR-181bmimicplusPDCD4overexpressionplasmid (lowerpanel).C: representative images;D
and E: quantitative analysis of the number of migrated cells. (F andG) Apoptosis assayswere performed 24 h after transfection of SW480 cells
with equal doseof controlmimic,miR-181bmimic, control inhibitor ormiR-181b inhibitor. F: representative images;G: quantitativeanalysis of the
apoptotic cell ratio. (H and I) Apoptosis assays were performed 24 h after transfection of SW480 cells with equal dose of the control mimic plus
control plasmid, miR-181b mimic plus control plasmid, control mimic plus PDCD4 overexpression plasmid, or miR-181b mimic plus PDCD4
overexpression plasmid. H: representative images; I: quantitative analysis of the apoptotic cell ratio. *P < 0.05; **P < 0.01; ***P < 0.001.
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lentivirus to produce functional intracellular miR-181b via the
endogenous miRNA processing pathway. As shown in
Supplemental Fig. 2A, the expression levels of mature miR-
181b were found to be 3–4-fold higher than the basal levels
when SW480 cells were infected with miR-181b overex-
pression lentivirus. Such fold change is biologically and
physiological relevant, because the altered miR-181b also
inhibited PDCD4 expression in SW480 cells (Fig. S2B and
S2C). Furthermore, overexpression of miR-181b by len-
tivirus also promoted cell proliferation and migration and
inhibited cell apoptosis in SW480 cells (Fig. S2D–H), to the
same degree as those obtained by using miR-181b mimic.
The results again verify that miR-181b regulates PDCD4
expression and consequently affects cell proliferation,
migration and apoptosis.
Because a single miRNA can target hundreds of genes
(Bartel, 2004), it is necessary to determine whether the
effects of miR-181b on CRC cells are derived from miR-
181b-mediated PDCD4 suppression. We next investigated
the exact contribution of the miR-181b-PDCD4 axis on CRC
cell proliferation, migration and apoptosis. We used an
siRNA and an overexpression plasmid to respectively
downregulate or upregulate PDCD4 protein levels. Efﬁcient
knockdown and overexpression of PDCD4 expression in
SW480 cells is shown in Fig. S1A–C. As a result, PDCD4
downregulation activated proliferation and migration and
suppressed apoptosis of SW480 cells, whereas PDCD4
overexpression had the opposite effect on cell proliferation,
migration and apoptosis (Fig. S1D–I). Thus, miR-181b and
PDCD4 have opposing effects on cell proliferation, migration
and apoptosis in CRC. We subsequently investigated whe-
ther overexpression of miR-181b-resistant PDCD4 (PDCD4
ORF) was sufﬁcient to rescue PDCD4 suppression by miR-
181b and attenuated the pro-proliferation, pro-migration and
anti-apoptotic effects of miR-181b on CRC cells. We trans-
fected SW480 cells with miR-181b mimic or PDCD4 over-
expression plasmid or co-transfected with miR-181b mimic
and PDCD4 overexpression plasmid. As expected, cells co-
transfected with the miR-181b mimic and PDCD4 overex-
pression plasmid showed signiﬁcantly lower proliferation
rates (Fig. 4B) and migration capabilities (Fig. 4C and 4E)
and higher apoptosis rates (Fig. 4H and 4I) compared to
cells transfected with miR-181b mimic alone. Thus,
restoration of PDCD4 expression can reverse miR-181b-in-
duced cell proliferation and migration and miR-181b-sup-
pressed cell apoptosis, suggesting that targeting of PDCD4
is one mechanism by which miR-181b exerts its oncomiR
function.
miR-181b promotes CRC growth in vivo by targeting
PDCD4
Finally, we investigated the effects of miR-181b and PDCD4
on the growth of CRC xenografts in mice. We infected
SW480 cells with a control lentivirus or a miR-181b over-
expression lentivirus, transfected cells with a PDCD4
overexpression plasmid, or co-transfected with a miR-181b
overexpression lentivirus and a PDCD4 overexpression
plasmid. The effects of lentiviral infection and plasmid
transfection are shown in Fig. S2A–C. Subsequently, we
subcutaneously implanted the infected or transfected
SW480 cells into 4-week-old nude mice. We evaluated
tumor growth 30 days after cell implantation. Xenograft
tumors from miR-181b-overexpressing group exhibited a
signiﬁcant increase in size and weight compared to the
control group, whereas the sizes and weight of tumors in the
group implanted with PDCD4-overexpressing cells dramati-
cally decreased (Fig. 5A and 5B). Additionally, PDCD4
overexpression attenuated the growth-promoting effects of
miR-181b (Fig. 5A and 5B), suggesting that miR-181b pro-
motes tumor growth by silencing PDCD4. We next isolated
and analyzed total RNA and protein from the tumors. Tumors
from the miR-181b-overexpressing group showed a signiﬁ-
cant increase in mature miR-181b expression compared to
tumors from the control group (Fig. 5C). Likewise, tumors
from the miR-181b-overexpressing group expressed
decreased PDCD4 protein levels compared to tumors from
the control group, whereas tumors from the PDCD4-over-
expressing group showed elevated PDCD4 protein levels
(Fig. 5D and 5E). Moreover, tumors with both miR-181b and
PDCD4 overexpression exhibited signiﬁcantly higher
PDCD4 levels compared to tumors overexpressing miR-
181b alone (Fig. 5D and 5E), suggesting that PDCD4
overexpression rescued miR-181b-mediated PDCD4 sup-
pression. We embed xenografted tumors in parafﬁn and then
performed H&E staining or examined using immunohisto-
chemical assays. H&E staining of xenograft tissues showed
increased cell mitosis in the miR-181b lentivirus group and
decreased mitosis in the PDCD4 plasmid group, whereas
xenografts with both miR-181b and PDCD4 overexpression
exhibited less cell mitosis compared to xenografts with miR-
181b overexpression (Fig. 5F). Immunohistochemical stain-
ing also revealed lower PDCD4 levels in tumors from mice
implanted with miR-181b-overexpressing cells, whereas
tumors from the PDCD4-overexpressing mice showed
increased PDCD4 protein levels (Fig. 5F and 5G). Finally, we
assessed the proliferative activity of tumor cells via Ki-67
immunohistochemical staining. The percentage of Ki-67-
positive tumor cells was increased in the group implanted
with miR-181b lentivirus and decreased in the group
implanted with PDCD4 plasmid (Fig. 5F and 5H). Likewise,
PDCD4 overexpression attenuated the pro-proliferative
effects of miR-181b overexpression (Fig. 5F and 5H). These
results are consistent with the in vitro ﬁndings, which ﬁrmly
validated the oncomiR role of miR-181b in CRC tumorigen-
esis through targeting of PDCD4.
DISCUSSION
Colorectal cancer is the third most common cancer world-
wide. At the molecular level, colorectal cancer arises from a
series of genetic and epigenetic alterations that inactivate
RESEARCH ARTICLE Yanqing Liu et al.











































































































































































































































































Figure 5. Effects of miR-181b and PDCD4 on the growth of CRC cell xenografted tumors in mice. SW480 cells were infected
with a control lentivirus or a lentivirus to overexpress miR-181b, or transfected with a PDCD4 overexpression plasmid, or co-
transfected with a miR-181b overexpression lentivirus and a PDCD4 overexpression plasmid. Differentially treated SW480 cells (3 ×
106 cells per mouse) were subcutaneously implanted into 4-week-old male SCID mice (5 mice per group), and tumor growth was
evaluated 30 days after cell implantation. (A) Representative images of tumors from the implanted mice. (B) Quantitative analysis of
xenografted tumor weights. (C) Quantitative RT-PCR analysis of miR-181b levels in tumors from implanted mice. (D and E) Western
blotting analysis of PDCD4 protein levels in tumors from implanted mice. D: representative images; E: quantitative analysis. (F–H)
H&E-stained sections and immunohistochemical staining for PDCD4 and Ki-67 in tumors from implanted mice. F: representative
images; G and H: quantitative analysis. *P < 0.05; **P < 0.01; ***P < 0.001.
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tumor suppressor genes and activate oncogenes. The list of
classical tumor suppressors and oncogenes has been
expanded to include miRNAs. Many studies have reported
the extensive alteration of miRNA proﬁles in the initiation and
developmental stages of CRC (Brunet Vega et al., 2013; Xu
et al., 2016). More importantly, new studies have established
the potential usefulness of miRNAs as therapeutic molecules
against cancer (Kota et al., 2009; Ma et al., 2010). For
example, aberrantly activated miRNAs can be silenced using
antagomirs (Krutzfeldt et al., 2005), and re-expression of
miRNAs that are lost in cancers can be achieved by the
induction of miRNA mimics (Kota et al., 2009). In this study,
we showed that miR-181b was upregulated in CRC tissues
and promoted cell proliferation and migration and sup-
pressed cell apoptosis in vitro and accelerated tumor growth
in vivo. Consistent with these results, miR-181 has also been
reported to be upregulated in various human cancer types,
including CRC (Nakajima et al., 2006; Xi et al., 2006;
Schetter et al., 2008; Degagne et al., 2014; Liu et al., 2014),
hepatocellular cancer (Wang et al., 2010a), breast cancer
(Mansueto et al., 2010) and ovarian cancer (Parikh et al.,
2014). During the CRC oncogenic process, miR-181 can
promote tumor growth and metastasis (Ji et al., 2014) and is
tightly associated with a poor prognosis (Nishimura et al.,
2012) and the chemoresponse of CRC patients (Nakajima
et al., 2006). Thus, it is possible that targeting of miR-181b
could control CRC development and ameliorate the symp-
toms, as shown by other groups (Krutzfeldt et al., 2005; Kota
et al., 2009; Ma et al., 2010). More research emphasis is
required to characterize the feasibility of targeting miR-181b
in CRC therapy and to develop simpliﬁed and cost-effective
manipulation methods.
PDCD4 is an important tumor suppressor in many can-
cers. In this study, we demonstrated that PDCD4 was dra-
matically downregulated in CRC tissues and could inhibit
proliferation and migration and promote apoptosis in CRC
cells and attenuate tumor growth in xenografted mice.
However, despite these advances in our understanding of
the essential role of PDCD4 in cancer progression, the
precise molecular mechanism through which PDCD4 is
downregulated during tumorigenesis remains largely
unknown. We searched for miRNAs that could target PDCD4
and experimentally validated miR-181b as a direct regulator
of PDCD4. However, because a single miRNA can target
multiple genes and multiple miRNAs can target a single
gene, miR-181b may have multiple different targets in
addition to PDCD4, and PDCD4 may be regulated by dif-
ferent miRNAs in addition to miR-181b. For example,
PDCD4 is regulated by miR-21 (Li et al., 2014) and miR-183
(Yang et al., 2014), and miR-181b can simultaneously target
WIF-1 (Ji et al., 2014) and CYLD (Iliopoulos et al., 2010).
Therefore, it is important to investigate how critical this new
pathway will be in the network of colorectal tumorigenesis
pathways. Because restoration of PDCD4 expression
attenuated the growth-promoting effects of miR-181b, tar-
geting of PDCD4 may be a mechanism by which miR-181b
exerts its oncomiR function. Therefore, modulation of
PDCD4 by miR-181b may explain why miR-181b is aber-
rantly overexpressed and PDCD4 is weakly expressed in
CRC tissues and why miR-181b upregulation can promote
cell growth and CRC formation.
It is necessary to ﬁnd out the upstream regulator of miR-
181b in CRC. In this study, we showed that STAT3 sup-
pressed PDCD4 through miR-181b activation. These ﬁnd-
ings add new clues to understanding the role of STAT3 in
CRC: activation of IL-6/STAT3 suppressed PDCD4 by
upregulating miR-181b, and therefore promoting the devel-
opment of CRC. Consistent with these results, a recent study
demonstrated that PDCD4 deﬁciency promoted the IL-6/
STAT3 pathway in mice (Wang et al., 2016). Thus, this study
delineates a novel regulatory network employing IL-6/
STAT3, miR-181b and PDCD4 as an integrated feedback
loop to ﬁne-tune cell function in colorectal cells. This sig-
naling pathway is crucial for normal colorectal cell function,
and any disruption in this pathway may result in misbehavior
of colorectal cells and CRC formation.
In summary, this study identiﬁed for the ﬁrst time that miR-
181b can target PDCD4 to promote CRC tumorigenesis.
Future research on miR-181b and PDCD4 will provide us
more knowledge about CRC and pave new approaches for
molecular therapeutics for this disease.
MATERIALS AND METHODS
Tissue samples
CRC tissue and paired normal adjacent tissue samples were
acquired from patients undergoing a surgical procedure at the
Afﬁliated Drum Tower Hospital of Nanjing University Medical School
(Nanjing, China). Both the tumor and non-tumor tissues were sent
for histological analysis and diagnostic conﬁrmation. Written consent
was obtained from all patients, and all protocols concerning the use
of patient samples in this study were approved by the Ethics Com-
mittee of Nanjing University. Tissue samples were immediately fro-
zen in liquid nitrogen at the time of surgery and stored at -80°C. All
experiments were performed in accordance with The Code of Ethics
of the World Medical Association (Declaration of Helsinki) and
approved guidelines of the Nanjing University. The clinical features
of the patients are listed in Supplemental Table 1.
Cell culture
The SW480, Caco2 and HT29 human CRC cell lines were pur-
chased from the Shanghai Institute of Biochemistry and Cell Biology,
Chinese Academy of Sciences (Shanghai, China). SW480 and
HT29 cells were cultured in RPMI-1640 (Gibco, Carlsbad, CA, USA)
supplemented with 10% fetal bovine serum (FBS, Gibco) in a
humidiﬁed incubator at 37°C with 5% CO2. Caco2 cells were cul-
tured in DMEM (Gibco) supplemented with 10% FBS (Gibco) in a
humidiﬁed incubator at 37°C with 5% CO2.
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RNA isolation and quantitative RT-PCR
Total RNA was extracted from the cultured cells and human tissues
using Trizol Reagent (Invitrogen, CA, USA) according to the man-
ufacturer’s instructions. TaqMan miRNA Assay Probes (Applied
Biosystems, Foster City, CA) were used to quantify mature miR-
181b according to the manufacturer’s instructions. Brieﬂy, 1 μg of
total RNA was reverse-transcribed to cDNA using a stem-loop RT
primer (Applied Biosystems) and AMV reverse transcriptase
(TaKaRa, Dalian, China). The reaction conditions were as follows:
16°C for 30 min, 42°C for 30 min and 85°C for 5 min. Quantitative
real-time PCR was performed using a TaqMan PCR kit on an
Applied Biosystems 7500 Sequence Detection System (Applied
Biosystems). The reactions were incubated in a 96-well optical plate
at 95°C for 5 min, followed by 40 cycles of 95°C for 15 s and 60°C for
1 min. All of the reactions were run in triplicate. After the reactions
were complete, the cycle threshold (CT) data were determined using
ﬁxed threshold settings, and the mean CT was determined from
triplicate PCRs. A comparative CT method was used to compare
each condition to the control reactions. U6 snRNA was used as an
internal control, and the relative amount of miRNA normalized
to U6 was calculated with the equation 2-ΔΔCT, in which ΔΔCT =
(CT miR-181b − CT U6)tumor − (CT miR-181b − CT U6)control.
To quantify PDCD4 and GAPDH mRNA, 1 μg of total RNA was
reverse transcribed to cDNA using Oligo d(T)18 primers (TaKaRa)
and AMV reverse transcriptase (TaKaRa). The reaction conditions
were as follows: 42°C for 60 min and 85°C for 5 min. Real-time PCR
was performed using the RT product, SYBR Green dye (Invitrogen)
and speciﬁc primers for PDCD4 and GAPDH. The primer sequences
were as follows: PDCD4 (sense): GTTGGCAGTATCCTTAG-
CATTGG; PDCD4 (antisense): TCCACATCAGTTGTGCTCATTAC;
GAPDH (sense): CGAGCCACATCGCTCAGACA; and GAPDH
(antisense): GTGGTGAAGACGCCAGTGGA. The reactions were
incubated at 95°C for 5 min, followed by 40 cycles of 95°C for 30 s,
60°C for 30 s and 72°C for 30 s. After the reactions were complete,
the CT values were determined by setting a ﬁxed threshold. The
relative amounts of PDCD4 mRNAs were normalized to GAPDH
using a similar method as described above.
Protein isolation and western blot
Cells or tissues were lysed in RIPA lysis buffer (Beyotime, Shanghai,
China) with freshly added PMSF (Beyotime, Shanghai, China) for 30
min on ice and were centrifuged at 12,000 × g at 4°C for 10 min. The
supernatant was collected, and the protein concentration was cal-
culated using a BCA protein assay kit (Thermo Scientiﬁc, Rockford,
IL, USA). Proteins were separated by SDS-PAGE (Bio-Rad). After
electrophoresis, the proteins were electrotransferred to PVDF
membranes (Roche) and then blocked with 5% skim milk for 1 h.
The membranes were then incubated with primary antibodies at 4°C
overnight. After 4 washes (10 min each) in TBST, the membranes
were incubated with horseradish peroxidase-conjugated secondary
antibody for 1 h at room temperature. After 4 washes (10 min each),
the membranes were incubated with Pierce SuperSignal West Pico
chemiluminescence substrate (Thermo). The same membrane was
also probed with a GAPDH antibody as a control. Antibodies against
PDCD4 and GAPDH were purchased from Santa Cruz Biotechnol-
ogy (sc-130545 and sc-25778, Santa Cruz, CA, USA).
miRNA overexpression and knockdown
miR-181b overexpression was achieved by transfecting CRC cells
with a miR-181b mimic, a synthetic double-stranded RNA oligonu-
cleotide mimicking the miR-181b precursor. miR-181b knockdown
was achieved by transfecting CRC cells with miR-181b inhibitor, a
chemically modiﬁed antisense oligonucleotide designed to target
mature miR-181b. Synthetic miR-181b mimic and inhibitor and
scrambled negative control RNAs (control mimic and inhibitor) were
purchased from GenePharma (Shanghai, China). SW480, Caco2
and HT29 cells were seeded in 6-well plates and transfected using
Lipofectamine 2000 (Invitrogen) on the following day when the cells
were approximately 60%–80% conﬂuent. For miR-181b overex-
pression experiments, 200 pmol of miR-181b mimic or control mimic
were added to each well. For miR-181b knockdown experiments,
200 pmol of miR-181b inhibitor or control inhibitor were added to
each well. At 6 h after transfection, the SW480 and HT29 cell
medium was changed to RPMI-1640 supplemented with 2% FBS
and the Caco2 cell medium was changed to DMEM supplemented
with 2% FBS. The cells were harvested 48 h after transfection for
total RNA or protein isolation.
Plasmid construction and siRNA interference assay
Mammalian expression plasmids designed to speciﬁcally express
the full-length open reading frame (ORF) of the human PDCD4 gene
were purchased from Genescript (Nanjing, China). An empty plas-
mid served as a negative control (control plasmid). siRNAs designed
to speciﬁcally silence PDCD4 or STAT3 were purchased from
GenePharma (Shanghai, China). A scrambled siRNA served as a
control. The siRNA sequences were as follows: si-PDCD4:
GCGGAAAUGUUAAGAGAUU; si-STAT3: CCACUUUGGUGUUU-
CAUAA. The overexpression plasmids and siRNAs were transfected
into CRC cells using Lipofectamine 2000 (Invitrogen) according to
the manufacturer’s instructions. Total RNA and protein were isolated
48 h after transfection and were assessed by quantitative RT-PCR
and western blot, respectively.
STAT3 activation and inhibition
To activate STAT3, recombinant human IL-6 (200-06, PeproTech)
was added to CRC cells at a ﬁnal concentration of 80 ng/mL. To
suppress STAT3 activity or expression, a STAT3-speciﬁc inhibitor
Stattic (S7947, Sigma) or an siRNA against STAT3 (sequence
described above) was added to CRC cells.
Luciferase reporter assay
A 378-bp fragment of the PDCD4 3′-UTR containing the presumed
miR-181b binding site was ampliﬁed by PCR with human genomic
DNA as a template. The following set of primers (with restriction
enzyme cut site and protection bases in the 5′ end) was used:
GGACTAGTGCTGCTGCTGTTGAGATA (forward primer) and
CCCAAGCTTCAAGGGAACACTAAGATTAA (reverse primer). The
378-bp fragment is located in the last exon of PDCD4. The two
additional sequences GGACTAGTand CCCAAGCTT in each primer
were specially added for restriction enzyme Spe I and Hind III,
respectively. The PCR fragment was digested with Spe I and Hind III
restriction enzyme and then inserted into the Spe I-Hind III sites of
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the pMIR-REPORT plasmid (Ambion, USA). Successful insertion
was conﬁrmed by DNA sequencing. To test binding speciﬁcity,
sequences that interacted with the miR-181b seed sequence were
mutated from GAATGT to CTTACA, and the synthetic PDCD4 3′-
UTR mutant fragment was inserted into an equivalent reporter
plasmid. For the luciferase reporter assays, SW480 cells were cul-
tured in 24-well plates, and each well was co-transfected with 0.2 µg
of ﬁreﬂy luciferase reporter plasmid, 0.2 µg of β-galactosidase (β-
gal) expression plasmid (Ambion), and equal amounts (50 pmol) of
miR-181b mimic, miR-181b inhibitor or the scrambled negative
control RNAs using Lipofectamine 2000 (Invitrogen). The β-gal
plasmid was used as a transfection efﬁciency control. The cells were
assayed using a luciferase assay kit 24 h post-transfection (Pro-
mega, Madison, WI, USA).
Cell proliferation assay
SW480 cells were plated at 2 × 104 cells per well in 96-well plates
and incubated overnight in RPMI-1640 supplemented with 10%
FBS. The cell proliferation index was measured using the Cell
Counting Kit-8 (CK04-500, Dojindo, Japan) at 12, 24, 36, 48, 60 and
72 h post-transfection according to the manufacturer’s instruction.
Absorbance was measured at a wavelength of 450 nm. All experi-
ments were performed in triplicate.
Cell migration assay
Cell migration assays were performed using Millipore 24-Well Milli-
cell (Millipore) plates containing an 8-μm pore membrane. The bot-
tom face of the membrane was coated with 1% gelatin. Cells were
harvested 24 h after transfection and suspended in FBS-free RPMI-
1640 culture medium. The cells were then added to the upper
chamber (2 ×104 cells/well) and 0.5 mL RPMI-1640 plus 20% FBS
was added to the lower compartment. The Transwell-containing
plates were incubated for 24 h in the incubator. After incubation, cells
that had entered the lower surface of the ﬁlter membrane were ﬁxed
with 4% paraformaldehyde for 25 min at room temperature. The
membrane was washed 3 times with distilled water and stained with
0.1% crystal violet in methanol for 15 min at room temperature. Cells
remaining on the upper surface of the ﬁlter membrane (non-migrant)
were gently scraped off with a cotton swab. The lower surfaces (with
migrant cells) were captured by photomicroscopy (BX51 Olympus,
Japan), and the cells were blindly counted (ﬁve ﬁelds per chamber).
Cell apoptosis assay
SW480 cell apoptosis was tested using an Annexin V-FITC/propid-
ium iodide (PI) staining assay. SW480 cells were cultured in 6-well
plates and transfected with the above-mentioned RNAs or plasmids.
To induce apoptosis, LPS (Sigma) was added to a ﬁnal concentra-
tion of 400 ng/mL. The cells were harvested after culturing for 24 h in
FBS-depleted medium. Flow cytometric analysis of apoptotic cells
was performed using an Annexin V-FITC/PI staining kit (BD Bio-
sciences, CA, USA). After washing with cold PBS, the cells were
resuspended in binding buffer (100 mmol/L HEPES, pH 7.4; 100
mmol/L NaCl; and 25 mmol/L CaCl2), followed by staining with
Annexin V-FITC/PI at room temperature in the dark for 15 min.
Apoptotic cells were then evaluated by gating the PI- and Annexin
V-positive cells using a ﬂuorescence-activated cell-sorting (FACS)
ﬂow cytometer (BD Biosciences, San Jose, CA, USA). All experi-
ments were performed in triplicate.
Establishment of tumor xenografts in mice
4-week-old male SCID (severe combined immune deﬁciency) mice
(nu/nu) were purchased from the Model Animal Research Center of
Nanjing University (Nanjing, China) and maintained under speciﬁc
pathogen-free conditions at Nanjing University. A 300-bp fragment
containing the miR-181b genomic sequence was obtained by PCR
ampliﬁcation of human DNA and cloned into a lentiviral expression
vector. SW480 cells were infected with a control lentivirus or a miR-
181b overexpression lentivirus, transfected with a PDCD4 overex-
pression plasmid, or co-transfected with a miR-181b overexpression
lentivirus and a PDCD4 overexpression plasmid. After infection and/
or transfection, SW480 cells were subcutaneously injected into
SCID mice (3 × 104 cells in 0.2 mL PBS per mouse, 5 mice per
group). The needle was inserted into the left side of the armpit,
midway down, 5 mm deep at a 45° angle. Mice were sacriﬁced 30
days after injection to remove the xenografted tumors, and the
weights of mice and tumors were measured. A portion of the tissues
was used for protein and total RNA extraction, and the remaining
tissue was ﬁxed in 4% paraformaldehyde for 24 h. The tissue was
processed for Hematoxylin and Eosin (H&E) staining or immuno-
histochemical staining for PDCD4 and Ki-67. All experiments were
approved by the Institutional Review Board of Nanjing University
(Nanjing, China) and performed in accordance with the U.K. Animals
(Scientiﬁc Procedures) Act (1986) and the guidelines of the
National Institutes.
Statistical analysis
All of the images of western blot assay and migration assay were
representative of at least three independent experiments. Quanti-
tative RT-PCR assay, luciferase reporter assay, proliferation assay
and apoptosis assay were performed in triplicate, and each indi-
vidual experiment was repeated several times. The results are
presented as the means ±SE of at least three independent experi-
ments. Observed differences were considered statistically signiﬁcant
at P < 0.05 using Student’s t-test.
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